Rhythm Pharmaceuticals (RYTM) PT Lowered to $141 at Goldman Sachs
Tweet Send to a Friend
Goldman Sachs analyst Corinne Jenkins lowered the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $141.00 (from $142.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
